Bulk Pharmaceutical API Sources for PEDIAZOLE

Bulk Pharmaceutical API Sources for PEDIAZOLE

Vendor	Vendor Homepage	Vendor Sku	API Url
Starshine Chemical		2023-05-7C00682
RR Scientific		R6441407

Bulk Active Pharmaceutical Ingredient (API) Sources for Pediazole

Last updated: February 19, 2026

This analysis identifies and categorizes key bulk active pharmaceutical ingredient (API) suppliers for Pediazole, a brand name for erythromycin ethylsuccinate oral suspension. The focus is on manufacturers with demonstrated capacity, regulatory compliance, and global reach to meet market demand for this pediatric antibiotic.

What is Pediazole and its API?

Pediazole is a prescription medication used to treat various bacterial infections in children. The active pharmaceutical ingredient in Pediazole is erythromycin ethylsuccinate. Erythromycin is a macrolide antibiotic that works by inhibiting bacterial protein synthesis. Ethylsuccinate is an ester form of erythromycin that improves oral absorption.

Erythromycin ethylsuccinate is synthesized through a chemical process involving erythromycin base and succinic anhydride. The manufacturing process requires strict quality control to ensure purity, potency, and compliance with pharmacopoeial standards, such as those set by the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP).

Leading Manufacturers of Erythromycin Ethylsuccinate API

The production of bulk erythromycin ethylsuccinate API is concentrated among a limited number of global manufacturers, primarily located in Asia. These companies possess the specialized infrastructure, technical expertise, and regulatory certifications necessary for pharmaceutical-grade API production.

Key Regions for API Manufacturing:

• China: Dominates global API production due to cost-effectiveness, large-scale manufacturing capabilities, and a well-established chemical industry.
• India: A significant player in API manufacturing, known for its strong regulatory compliance and diverse product portfolio, often competing directly with Chinese manufacturers.

Table 1: Prominent Erythromycin Ethylsuccinate API Manufacturers

Manufacturer Name	Country	Primary Focus	Regulatory Approvals (Examples)	Notes
Lianyungang PharmaChem	China	Broad range of APIs, including macrolides	FDA, EDQM, WHO GMP	Large-scale producer with a significant share of the global erythromycin market. Focus on bulk API supply for generic drug manufacturers.
Hebei Tianyi Chemical	China	Antibiotic APIs, intermediates	FDA, EDQM	Established manufacturer with a strong reputation for antibiotic production. Supplies API to both domestic and international markets.
Zydus Lifesciences (formerly Cadila Healthcare)	India	Integrated pharmaceutical company, API division	FDA, EDQM, WHO GMP	While Zydus is a finished dosage form manufacturer, its API division is a significant global supplier. Known for quality control and adherence to international standards.
Divi's Laboratories	India	API manufacturing, custom synthesis	FDA, EDQM, PMDA (Japan)	Renowned for its state-of-the-art manufacturing facilities and robust quality management systems. A key supplier for numerous major pharmaceutical companies.
Siegfried AG	Switzerland	Contract development and manufacturing (CDMO)	FDA, EDQM	While a CDMO, Siegfried has capabilities in API synthesis and can be a source for erythromycin ethylsuccinate, particularly for clients requiring specialized development or smaller-scale, high-quality production.

Source: Industry reports, company websites, regulatory databases.

These manufacturers typically operate under strict Good Manufacturing Practices (GMP) guidelines, ensuring the quality and safety of their APIs. Regulatory approvals from agencies like the U.S. Food and Drug Administration (FDA), the European Directorate for the Quality of Medicines & HealthCare (EDQM), and the World Health Organization (WHO) are critical indicators of compliance and market access.

Supply Chain Considerations for Erythromycin Ethylsuccinate API

The supply chain for Pediazole API involves several stages, from raw material sourcing to finished API delivery. Manufacturers must manage these stages efficiently to ensure consistent supply and cost control.

Key Supply Chain Components:

• Raw Material Sourcing: Erythromycin base is the primary precursor. Its production is often linked to fermentation processes, requiring access to specific microbial strains and fermentation technology. Suppliers of key chemical reagents used in esterification are also critical.
• Manufacturing and Synthesis: The chemical synthesis of erythromycin ethylsuccinate involves esterification of erythromycin base. This step requires specialized reactors and precise process control.
• Quality Control and Testing: Rigorous analytical testing is performed at various stages to ensure the API meets pharmacopoeial specifications for identity, purity, strength, and absence of impurities.
• Packaging and Logistics: APIs are typically packaged in inert containers to maintain stability during storage and transport. Global logistics networks are essential for timely delivery to pharmaceutical formulation sites.
• Regulatory Documentation: Manufacturers must maintain extensive documentation, including Drug Master Files (DMFs), to support their API's registration with regulatory authorities worldwide.

Challenges in the Supply Chain:

• Raw Material Volatility: Fluctuations in the price and availability of fermentation-derived erythromycin base can impact API costs.
• Regulatory Scrutiny: Increasing regulatory oversight on API manufacturing, particularly regarding impurity profiles and supply chain transparency, demands continuous investment in quality systems.
• Geopolitical Factors: Trade policies, tariffs, and geopolitical stability in major manufacturing regions can disrupt supply.
• Capacity Management: Ensuring sufficient manufacturing capacity to meet global demand, especially during periods of high infection rates or supply chain disruptions, is crucial.

Regulatory Landscape for API Suppliers

Manufacturers of erythromycin ethylsuccinate API must navigate a complex and evolving regulatory landscape. Compliance is not merely a requirement but a prerequisite for market entry and sustained business operations.

Key Regulatory Aspects:

• Good Manufacturing Practices (GMP): Adherence to current GMP standards (cGMP) as defined by regulatory bodies such as the FDA, EMA, and WHO is mandatory. This covers all aspects of production, from facility design and personnel training to process validation and record-keeping.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. A DMF is a submission to the agency that contains detailed information about the manufacturing process, facilities, quality control, and packaging of the API. This allows finished drug product manufacturers to reference the DMF in their own drug applications without disclosing proprietary API information.
• Inspections and Audits: Regulatory agencies conduct periodic inspections of API manufacturing sites to verify compliance with GMP. Pharmaceutical companies also conduct audits of their API suppliers as part of their vendor qualification process.
• Pharmacopoeial Standards: APIs must meet the specifications outlined in relevant pharmacopoeias, such as the USP, EP, and Japanese Pharmacopoeia (JP). These standards define acceptable limits for impurities, assay, and other critical quality attributes.
• Impurity Profiling: Regulatory authorities place increasing emphasis on the identification, qualification, and control of impurities, including process-related impurities and potential genotoxic impurities. Manufacturers must develop robust analytical methods and control strategies.
• Supply Chain Transparency: Regulators and pharmaceutical companies are demanding greater transparency in the API supply chain, including the sourcing of raw materials and the qualification of secondary suppliers.

Impact of Regulatory Compliance:

• Market Access: Successful navigation of regulatory requirements is essential for gaining approval to sell API in regulated markets like the United States, Europe, and Japan.
• Quality Assurance: Robust regulatory compliance programs are intrinsically linked to the production of high-quality, safe, and effective APIs.
• Competitive Advantage: Manufacturers with strong regulatory track records and current certifications often have a competitive advantage in securing long-term supply contracts with major pharmaceutical companies.
• Risk Mitigation: Proactive compliance helps mitigate risks associated with regulatory non-compliance, such as product recalls, import alerts, or loss of market authorization.

Market Dynamics and Demand for Pediazole API

The demand for erythromycin ethylsuccinate API is primarily driven by the global market for pediatric antibiotics. While newer macrolides and other antibiotic classes exist, erythromycin remains a widely used and cost-effective option for treating specific bacterial infections in children.

Factors Influencing Demand:

• Pediatric Population Growth: An increasing global pediatric population directly correlates with demand for pediatric medications.
• Prevalence of Bacterial Infections: The incidence of common childhood infections, such as respiratory tract infections and ear infections, influences the demand for antibiotics.
• Antibiotic Stewardship: While global efforts promote antibiotic stewardship to combat resistance, erythromycin ethylsuccinate is still a preferred agent for certain indications where resistance patterns are favorable.
• Generic Competition: The availability of generic Pediazole formulations drives demand for cost-competitive erythromycin ethylsuccinate API.
• Emerging Markets: Growing healthcare access and expenditure in emerging markets contribute to increased demand for essential antibiotics.

Competitive Landscape for API Suppliers:

The erythromycin ethylsuccinate API market is characterized by:

• Price Sensitivity: Given the extensive use of generic Pediazole, price is a significant factor for API procurement. Chinese and Indian manufacturers often compete aggressively on price.
• Quality and Reliability: Despite price pressures, finished dosage form manufacturers prioritize API suppliers with a proven track record of consistent quality, regulatory compliance, and supply reliability.
• Scale of Production: The ability to produce large volumes of API consistently is a key differentiator for major suppliers.
• Technical Support: API manufacturers that offer strong technical support, including assistance with regulatory filings and troubleshooting, are highly valued.

Key Takeaways

• Erythromycin ethylsuccinate is the bulk active pharmaceutical ingredient (API) for Pediazole, a pediatric antibiotic.
• Manufacturing of erythromycin ethylsuccinate API is concentrated in China and India, with Lianyungang PharmaChem, Hebei Tianyi Chemical, Zydus Lifesciences, and Divi's Laboratories being prominent suppliers.
• Key supply chain considerations include raw material sourcing, manufacturing process control, rigorous quality testing, and global logistics.
• Regulatory compliance, including adherence to cGMP, filing of DMFs, and meeting pharmacopoeial standards, is paramount for API manufacturers.
• Demand for erythromycin ethylsuccinate API is influenced by pediatric population growth, infection prevalence, generic market dynamics, and emerging market expansion.
• The API market is competitive, with price, quality, production scale, and regulatory standing being critical factors for suppliers.

FAQs

1. What are the primary impurities to monitor in erythromycin ethylsuccinate API? Key impurities include residual solvents from synthesis, unreacted erythromycin base, degradation products of erythromycin ethylsuccinate, and potential process-related impurities. Manufacturers must adhere to pharmacopoeial limits and conduct thorough impurity profiling.

2. How does the ethylsuccinate ester form impact erythromycin's efficacy compared to erythromycin base? The ethylsuccinate ester form of erythromycin is designed to enhance oral absorption, leading to higher serum concentrations compared to erythromycin base when administered orally. This improved bioavailability is crucial for achieving effective therapeutic levels in treating infections.

3. What is the typical shelf life of erythromycin ethylsuccinate API? The typical shelf life of erythromycin ethylsuccinate API, when stored under recommended conditions (e.g., protected from light and moisture, at controlled room temperature), is generally between two to three years. Specific stability data are provided by the manufacturer based on their stability studies.

4. Can API manufacturers provide customized specifications for erythromycin ethylsuccinate? While core pharmacopoeial specifications are non-negotiable, API manufacturers may offer customized specifications for certain parameters, such as specific particle size distribution or polymorphic forms, provided these do not compromise safety, efficacy, or regulatory compliance and are supported by appropriate validation.

5. What are the current regulatory trends impacting erythromycin ethylsuccinate API manufacturers? Current trends include increased scrutiny on impurity control, particularly genotoxic impurities; demands for greater supply chain transparency and traceability; ongoing inspections for cGMP compliance; and evolving requirements for environmental impact assessments in manufacturing processes.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry Drug Master Files: A. Structure and Content. Retrieved from https://www.fda.gov/media/73845/download [2] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-development/good-manufacturing-practice [3] United States Pharmacopeia. (n.d.). Erythromycin Ethylsuccinate. In USP-NF Online. [4] World Health Organization. (n.d.). WHO GMP documents. Retrieved from https://www.who.int/teams/health-product-and-systems-information/quality-assurance/good-manufacturing-practices